Endoglin (CD105) and Vascular Endothelial Growth Factor as Prognostic Markers in Prostatic Adenocarcinoma

Department of Surgery, Drexel University, Filadelfia, Pennsylvania, United States
American Journal of Clinical Pathology (Impact Factor: 2.51). 04/2007; 127(4):572-9. DOI: 10.1309/X6NXYE57DLUE2NQ8
Source: PubMed


We studied endoglin and vascular endothelial growth factor (VEGF) expression as prognostic markers in prostatic adenocarcinoma in 50 radical prostatectomy specimens. Cases were further categorized by Gleason score as follows: 8 to 10, 9 cases; 7(4 + 3), 9 cases; 7 (3 + 4), 14 cases; 6, 13 cases; and 4 or 5, 5 cases. All cases were immunostained for endoglin, CD31, and VEGF. Positively stained microvessels were counted in densely vascular foci in a x 400 field. VEGF staining intensity was scored on a 2-tiered scale. Results were correlated with survival and other parameters. Endoglin demonstrated significantly more microvessels than did CD31 (mean +/- SD, 37 +/- 15 vs 22 +/- 17; P < .001). VEGF expression was low in 21 cases (42%) and high in 29 (58%). Endoglin correlated positively with Gleason score, lymph node metastases, tumor stage, and preoperative prostate-specific antigen level (P < .05) but not with CD31. VEGF correlated significantly with angiolymphatic invasion and Gleason score (P < .05). A high endoglin microvessel count and VEGF expression correlated with shorter survival. Endoglin is a more specific and sensitive marker for tumor angiogenesis than CD31 and may serve as a prognostic marker for prostatic adenocarcinoma.

Full-text preview

Available from:
  • Source
    • "The currently accepted standard method for quantifying tumor angiogenesis is to assess MVD based on immunohistochemistry (IHC). Groups of scientists had chosen different antibodies to evaluate MVD in various tumors [17, 22–26]. Our group had found in previous studies that the choice of IHC marker used for endothelial cells detection may influence the results, and the CD31 antibody as an endothelial marker provides the most unequivocal and conspicuous results [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis (neoangiogenesis), a process of neovascularization, is an essential step for local tumor growth and distant metastasis formation. We have analysed angiogenesis status: vascular architecture, microvessel density, and vascular endothelial growth factors expression in 62 adrenal pheochromocytomas: 57 benign and 5 malignant. Immunohistochemical evaluation revealed that vascular architecture and vessel density are different in the central and subcapsular areas of the tumor. Furthermore, we have observed a strong correlation between number of macrophages and microvessel density in the central and subcapsular areas of the tumor and between the expression of VEGF-A in tumor cells and microvessel density in central and subcapsular areas of the tumor. Secondary changes in these tumors influence the results and both vascular architecture and microvessel density are markedly disturbed by hemorrhagic and cystic changes in pheochromocytomas. These changes are partially caused by laparoscopic operation technique. However, no differences in vascular parameters were found between pheochromocytomas with benign and malignant clinical behavior. Our observation showed that analysis of angiogenesis, as a single feature, does not help in differentiating malignant and benign pheochromocytomas and has no independent prognostic significance. On the other hand, high microvessel density in pheochromocytoma is a promising factor for antiangiogenic therapy in malignant cases.
    Full-text · Article · Sep 2014 · International Journal of Endocrinology
  • Source
    • "Karin described how NF-í µí¼…B and angiogenesis are an important link driving inflammation towards cancer [50] and in the same year Folkman highlighted that the oncogene-driven transition process from inflammation to cancer also influenced the host's prognosis [51]. Angiogenesis has received a lot of attention due to its influence on the tumour grade, metastasis, and therefore patients' prognosis; over-expression of its hallmark cytokine, vascular endothelial growth factor (VEGF), is well known amongst various malignant cancers often with poorer outcomes [52] [53] [54] [55] [56]. It is a crucial part of the tumour microenvironment [57] and the literature so seems to map out more pathways of Th17-mediated angiogenesis [25, 27, 33, 51, 57–91] than it does for its inhibition [64, 79, 80, 92–98]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: With 7.6 million deaths globally, cancer according to the World Health Organisation is still one of the leading causes of death worldwide. Interleukin 17 (IL-17) is a cytokine produced by Th17 cells, a T helper cell subset developed from an activated CD4+ T-cell. Whilst the importance of IL-17 in human autoimmune disease, inflammation, and pathogen defence reactions has already been established, its potential role in cancer progression still needs to be updated. Interestingly studies have demonstrated that IL-17 plays an intricate role in the pathophysiology of cancer, from tumorigenesis, proliferation, angiogenesis, and metastasis, to adapting the tumour in its ability to confer upon itself both immune, and chemotherapy resistance. This review will look into IL-17 and summarise the current information and data on its role in the pathophysiology of cancer as well as its potential application in the overall management of the disease.
    Full-text · Article · Jul 2014 · Mediators of Inflammation
  • Source
    • "CD105 expression has been detected by immunohistochemistry for the evaluation of angiogenesis in premalignant and malignant lesions. It is considered more neoangiogenesis-specific than pan-endothelial CD34 and CD31 antibodies and might have a more significant prognostic value for some cancers [14,17,18]. The role of angiogenesis in chronic liver disease, liver premalignant lesions and liver cancer has also been studied using pan-endothelial antibodies [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is a proliferative process resulting in the development of new blood vessels from existing endothelial cells and is considered crucial for tumor growth and metastasis. Tumor angiogenesis can be quantified by microvascular density (MVD), which is evaluated in highly vascularized tumor areas (hot spots) by immunohistochemical assays using CD34 and CD31 pan-endothelial antibodies. More recently, CD105 has been successfully used for some tumor types because it could discriminate neovascularization. The expression of CD34 and CD105 in hepatocellular carcinomas (HCC) and hepatic precancerous lesions has been reported--although the results for CD105 are controversial--but to the best our knowledge, CD105 has not been previously investigated in dysplastic nodules (DN). We investigated and compared MVD-CD34 and MVD-CD105 immunoexpression in tissues containing different stages of hepatocarcinogenesis, including DN. A total of 31 regenerative nodules (RN), 26 DN and 25 small HCC from explants were used for immunohistochemical tests with CD34 and CD105 antibodies. Antibody expression was quantified by computerized image analysis measurement of MVD, areas containing highly positive endothelial cells within the nodules. The median MVD for CD34 was higher in HCC than in DN and RN (p < 0.01), and was higher in DN compared with RN (p = 0.033). In contrast, MVD with CD105 was higher in RN, and the difference was significant in RN and DN compared with HCC (p = 0.019 and p = 0.012, respectively). When MVD with CD34 and CD105 were compared within a single group, there was a significant predominance of CD105 in RN and DN (p < 0.01). In addition, MVD-C34 in HCC predominated compared with MVD-CD105, but the difference was not statistically significant (p = 0.128). This study identified a close relationship between CD105 and liver cirrhosis, and that CD34 antibody is a good endothelial marker for hepatic carcinogenesis. There was no difference between the use of CD105 and CD34 antibodies in preneoplastic lesions.
    Full-text · Article · Feb 2014 · BMC Cancer
Show more